ReviewCurrent topics in behavioral neurosciences2021
Pharmacotherapeutic Strategies and New Targets in OCD.
Review in Current topics in behavioral neurosciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Serotonergic underpinnings of obsessive-compulsive disorder: A systematic review and meta-analysis of neuroimaging findings.Psychiatry and clinical neurosciences · 2025Pooled it
- Mechanisms of Selective Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: Cortico-Striatal Circuitry, Glutamatergic Dysregulation, and Neuroplastic Constraints.Molecular neurobiology · 2026Review
- Review
- Efficacy and safety profile of vortioxetine as an add-on molecule in obsessive-compulsive disorder: a randomized double-blinded placebo-controlled superiority trial - a study protocol.BMC psychiatry · 2025Article
- [Update on obsessive-compulsive and related disorders].Der Nervenarzt · 2025Article
- Role of Methylphenidate Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder: A Case Series.Cureus · 2025Article
- New Agents in the Treatment of Psychiatric Disorders: What Innovations and in What Areas of Psychopathology?Pharmaceuticals (Basel, Switzerland) · 2025Review
- Hereditary Patterns and Genetic Associations in Obsessive-Compulsive Disorder (OCD): Neuropsychiatric Insights, Genetic Influences, and Treatment Perspectives.Current gene therapy · 2025Review
- Therapeutic effects of striatal dopaminergic modulation on idiopathic dystonia and OCD in humans: insights from the striosome hypothesis.Frontiers in human neuroscience · 2025Article
- Mechanisms of DBS: from informational lesions to circuit modulation and implications in OCD.Frontiers in human neuroscience · 2025Review
- Psilocybin in pharmacotherapy of obsessive-compulsive disorder.Pharmacological reports : PR · 2024Review
- Drug repurposing for obsessive-compulsive disorder using deep learning-based binding affinity prediction models.AIMS neuroscience · 2024Article
- A closer look to neural pathways and psychopharmacology of obsessive compulsive disorder.Frontiers in behavioral neuroscience · 2023Review
- Therapies for obsessive-compulsive disorder: Current state of the art and perspectives for approaching treatment-resistant patients.Frontiers in psychiatry · 2023Review
- Repeating patterns: Predictive processing suggests an aesthetic learning role of the basal ganglia in repetitive stereotyped behaviors.Frontiers in psychology · 2022Article
- Specialty knowledge and competency standards for pharmacotherapy for adult obsessive-compulsive disorder.Psychiatry research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Effective pharmacological and psychotherapeutic treatments are well established for obsessive-compulsive disorder (OCD). Serotonin reuptake inhibitors (SRIs) are first-line treatment and are of benefit to about half of patients. Augmentation of SRI treatment with low-dose neuroleptics is an evidence-based second-line strategy. Specialty psychotherapy is also used as both first-line and second-line treatment and can benefit many. However, a substantial number of patients do not respond to these treatments. New alternatives are urgently needed. This review summarizes evidence for these established pharmacotherapeutic strategies, and for others that have been investigated in refractory disease but are not supported by the same level of evidence. We focus on three neurotransmitter systems in the brain: serotonin, dopamine, and glutamate. We summarize evidence from genetic, neuroimaging, animal model, and other lines of investigation that probe these three systems in patients with OCD. We also review recent work on predictors of response to current treatments. While many studies suggest abnormalities that may provide insight into the pathophysiology of the disorder, most studies have been small, and non-replication of reported findings has been common. Nevertheless, the gradual accrual of evidence for neurotransmitter dysregulation may in time lead the way to new pharmacological strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.